Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Bristol-Myers Squibb Co shares valued at $16,719 were sold by Short Bartie Wendy on Aug 02 ’25. At $44.23 per share, Short Bartie Wendy sold 378 shares. The insider’s holdings dropped to 5,066 shares worth approximately $0.24 million following the completion of this transaction.
Also, Hickey Benjamin sold 97 shares, netting a total of over 3,702 in proceeds. Following the sale of shares at $38.01 each, the insider now holds 0 shares.
Before that, Hirawat Samit had added 4,250 shares to its account. In a trade valued at $202,215, the EVP,Chief Med.Offr.,Drug Dev. bought Bristol-Myers Squibb Co shares for $47.58 each. Upon closing the transaction, the insider’s holdings increased to 4,250 shares, worth approximately $4.0 million.
As published in a research note from Daiwa Securities on August 05, 2025, Bristol-Myers Squibb Co [BMY] has been rated down from an Outperform to a Neutral and the price target has been revised to $42. Analysts at Piper Sandler started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of April 22, 2025, Cantor Fitzgerald has initiated its “Neutral” rating for BMY. Earlier on December 16, 2024, Jefferies upgraded its rating. Their new recommendation was “a Buy” for BMY stock which previously was a “a Hold”.
Analyzing BMY Stock Performance
On last trading session, Bristol-Myers Squibb Co [NYSE: BMY] rose 2.79% to $47.85. The stock’s lowest price that day was $46.35, but it reached a high of $47.87 in the same session. During the last five days, there has been a surge of approximately 6.76%. Over the course of the year, Bristol-Myers Squibb Co shares have jumped approximately 2.42%. Shares of the company reached a 52-week high of $63.33 on 03/11/25 and a 52-week low of $42.96 on 07/31/25.
Support And Resistance Levels for Bristol-Myers Squibb Co (BMY)
According to the 24-hour chart, there is a support level at 46.84, which, if violated, would cause prices to drop to 45.84. In the upper region, resistance lies at 48.36. The next price resistance is at 48.88. RSI (Relative Strength Index) is 56.11 on the 14-day chart, showing neutral technical sentiment.
Is Bristol-Myers Squibb Co subject to short interest?
Stocks of Bristol-Myers Squibb Co saw a sharp steep in short interest on 2025-07-31 dropping by -8.53 million shares to 30.92 million. Data from Yahoo Finance shows that the short interest on 2025-06-30 was 39.45 million shares. A decline of -27.58% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 2.28 of the overall float, the days-to-cover ratio (short ratio) decline to 2.28.
Which companies own the most shares of Bristol-Myers Squibb Co (BMY)?
In terms of Bristol-Myers Squibb Co share price expectations, FactSet research, analysts set an average price target of 66.5 in the next 12 months, up nearly 42.86% from the previous closing price of $46.55. Analysts anticipate Bristol-Myers Squibb Co stock to reach 84 by 2025, with the lowest price target being 42. In spite of this, 14 analysts ranked Bristol-Myers Squibb Co stock as Hold at the end of 2025. On December 10, 2024, BofA Securities assigned a price target of “a Neutral” to the stock and resumed coverage with a $63.
